Zoetis Investors Face July 27 Deadline in Securities Fraud Lawsuit

The pending litigation centers on claims that Zoetis executives issued false statements about the company's market share and sales growth. Specifically, the complaint alleges the firm failed to disclose that veterinarian adoption of the canine pain treatment Librela was declining following FDA safety warnings about neurological complications. Furthermore, the lawsuit contends that Zoetis' Simparica Trio and its dermatology line, including Apoquel and Cytopoint, were losing ground to more affordable or newly launched competitors in a cooling market.

Investors who purchased shares during the defined class period may be eligible for compensation through a contingency fee arrangement. While a class action has been filed, no class has been certified, meaning shareholders are not currently represented by counsel unless they retain one. Those interested in participating or seeking appointment as lead plaintiff can contact attorney Phillip Kim at 866-767-3653 or via the Rosen Law Firm website.